VERA - Vera Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$76.40
DETAILS
HIGH:
$95.00
LOW:
$33.00
MEDIAN:
$90.00
CONSENSUS:
$76.40
UPSIDE:
124.44%
About Vera Therapeutics, Inc. (https://veratx.com)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director | 1975 | $1,214,400 USD |
| David L. Johnson | Chief Opearating Officer | 1970 | $798,600 USD |
| Robert Brenner | Chief Medical Officer | 1968 | $797,040 USD |
| Sean Grant | Chief Financial Officer | 1985 | $793,920 USD |
| William D. Turner | Chief Regulatory Officer | 1967 | $737,880 USD |
| Amit Sharma FACP FASN FNKF | Executive Vice President of Medical Affairs | 1969 | – |
| Carrie Helland | Senior Vice President of Product & Portfolio Strategy and Management | – | – |
| Debra Charlesworth | Vice President of Corporate Communications | – | – |
| Emma Haywood | Vice President of Marketing | – | – |
| Gary Barrera | Senior Vice President of Regulatory Affairs & Quality Assurance | – | – |
| Jane Wright-Mitchell | Chief Legal Officer & Secretary | 1969 | – |
| Jim Harrington | SVP of Intellectual Property | – | – |
| Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | 1972 | – |
| Julie Person | Chief People Officer | 1973 | – |
| Lijie Zhong | Senior Vice President of Biometrics | – | – |
| Matthew Skelton | Chief Commercial Officer | 1965 | – |
| Raffaella Faggioni | SVP of Clinical Pharmacology & Translational Medicine | – | – |
| S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations | – | – |
| Thomas-Christian Mix | Executive Vice President of Clinical Development | 1967 | – |
| Tom Doan | Executive Vice President of Development Operations | 1972 | – |